Pharmacological targeting of σ2R/TMEM97 has neuroprotective effects in a number of models of neurodegenerative conditions, including traumatic brain injury (19), Huntington's disease (20), and retinal ganglion cell degeneration (21). Here, TMEM97 is linked to Huntington disease.